Related Experiment Video
Updated: Jun 4, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Arterial interventions for renovascular hypertension
Shams Iqbal1, Ashish Sharma, Stephan T Wicky
1Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Seminars in Interventional Radiology
|February 18, 2011
Summary
Renovascular hypertension, often caused by renal artery stenosis, can be effectively treated with percutaneous intervention like angioplasty and stenting, especially in carefully selected patients.
Area of Science:
- Cardiology
- Nephrology
- Interventional Radiology
Background:
- Renovascular hypertension is a significant cause of secondary hypertension, frequently affecting younger individuals.
- The primary underlying pathology is renal artery stenosis, most commonly due to atherosclerosis (90%) and fibromuscular dysplasia.
- Both atherosclerosis and fibromuscular dysplasia are treatable with percutaneous interventional therapies.
Purpose of the Study:
- To review the role of percutaneous intervention in managing renovascular hypertension.
- To discuss the techniques of renal angioplasty and stenting for this condition.
Main Methods:
- Review of current literature on percutaneous interventions for renal artery stenosis.
- Analysis of outcomes for renal angioplasty and stenting in well-selected patients.
Main Results:
- Percutaneous intervention, including renal angioplasty and stenting, offers good outcomes in appropriately selected patients.
- Advances in medical therapies have improved blood pressure control, complementing interventional procedures.
Conclusions:
- Percutaneous intervention is a valuable treatment option for renovascular hypertension caused by renal artery stenosis.
- Renal angioplasty and stenting are key techniques in the interventional management of this condition.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...